Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer

被引：0
|
作者：
Ni, M. [1 ]
Zhou, L. [1 ]
Lu, Y. [2 ]
Zhang, L. [2 ,3 ]
Li, X. [4 ]
Chen, M. [2 ]
Yang, A. [5 ]
Zhang, L. [2 ,3 ]
Xu, F. [1 ]
Yuan, Z. [1 ]
Wang, S. [1 ]
Shi, Y. [1 ]
An, X. [5 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou, Peoples R China
[2] Guangxi Med Univ, Affiliated Tumor Hosp, Guangxi, Peoples R China
[3] Puning Peoples Hosp, Puning, Peoples R China
[4] Guangzhou Panyu Cent Hosp, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Dept Breast Oncol, Ctr Canc, Collaborat Innovat Ctr Canc Med,State Key Lab Onc, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.198
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
63P
引用
下载
收藏
页码：S1490 / S1490
页数：1
相关论文
共 50 条
  • [11] Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer
    Okazaki, Misato
    Horimoto, Yoshiya
    Tanabe, Masahiko
    Ichikawa, Yuko
    Tokuda, Emi
    Arakawa, Atsushi
    Kobayashi, Toshiyuki
    Saito, Mitsue
    MEDICAL ONCOLOGY, 2018, 35 (04)
  • [12] Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer
    Misato Okazaki
    Yoshiya Horimoto
    Masahiko Tanabe
    Yuko Ichikawa
    Emi Tokuda
    Atsushi Arakawa
    Toshiyuki Kobayashi
    Mitsue Saito
    Medical Oncology, 2018, 35
  • [13] Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center
    Bergamino Sirven, Milana
    Fernandez-Ortega, Adela
    Stradella, Agostina
    Morilla, Idoia
    Falo, Catalina
    Vazquez, Silvia
    Castany, Roser
    Villanueva, Rafael
    Recalde, Sabela
    Navarro Perez, Valenti
    Gil-Gil, Miguel
    Pernas, Sonia
    BMC PHARMACOLOGY & TOXICOLOGY, 2019, 20 (01):
  • [14] Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
    Landry, Chrystal A.
    Blanter, Julia
    Ru, Meng
    Fasano, Julie
    Klein, Paula
    Shao, Theresa
    Bhardwaj, Aarti
    Tiersten, Amy
    ONCOLOGY, 2023,
  • [15] Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
    Landry, Chrystal A.
    Blanter, Julia
    Ru, Meng
    Fasano, Julie
    Klein, Paula
    Shao, Theresa
    Bhardwaj, Aarti
    Tiersten, Amy
    ONCOLOGY, 2023,
  • [16] Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-Negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
    Landry, Chrystal A.
    Blanter, Julia
    Ru, Meng
    Fasano, Julie
    Klein, Paula
    Shao, Theresa
    Bhardwaj, Aarti
    Tiersten, Amy
    ONCOLOGY, 2024, 102 (01) : 9 - 16
  • [17] Dose escalation of POL6326 in combination with eribulin in HER2-negative relapsed metastatic breast cancer (mBCa) patients (pts).
    Simon, Sonia Pernas
    Cortes, Javier
    Ademuyiwa, Foluso Olabisi
    Lopez-Tarruella, Sara
    Manso, Luis
    Kaufman, Peter
    Hooftman, Leon W.
    Romagnoli, Barbara
    Perez-Fidalgo, Jose Alejandro
    Pluard, Timothy J.
    Weilbaecher, Katherine N.
    Pardo, Patricia Gomez
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [18] Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer
    Matsuda, Naoko
    Wang, Xiaoping
    Lim, Bora
    Krishnamurthy, Savitri
    Alvarez, Ricardo H.
    Willey, Jie S.
    Parker, Charla A.
    Song, Juhee
    Shen, Yu
    Hu, Jianhua
    Wu, Wenhui
    Li, Nan
    Babiera, Gildy V.
    Murray, James L.
    Arun, Banu K.
    Brewster, Abenaa M.
    Reuben, James M.
    Stauder, Michael C.
    Barnett, Chad M.
    Woodward, Wendy A.
    Le-Petross, H. T. Carisa
    Lucci, Anthony
    DeSnyder, Sarah M.
    Tripathy, Debu
    Valero, Vicente
    Ueno, Naoto T.
    JAMA ONCOLOGY, 2018, 4 (09) : 1207 - 1213
  • [19] Safety and immunologic activity of anakinra in HER2-negative metastatic breast cancer (MBC).
    O'Shaughnessy, Joyce
    Young, Robyn R.
    Levin, Maren K.
    Baisch, Jeanine
    Timis, Roxana
    Muniz, Luz Stella
    Turner, Jacob
    Pascual, Virginia
    Palucka, Karolina
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [20] Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study
    Jiang, Mingxia
    Shao, Bin
    Wan, Donggui
    Liu, Jiaxuan
    He, Maiyue
    Chai, Yue
    Sang, Die
    Wang, Jiayu
    Ma, Fei
    Fan, Ying
    Yuan, Peng
    Xu, Binghe
    Li, Qiao
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
12345